NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials

By Nikita Chaurasia  Date: 2020-08-03

NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials

U.S.-based pharmaceutical company NeuroRx Inc., along with Relief Therapeutics Holding AG, a Swiss drug development company, have reportedly declared that aviptadil (RLF-100) clinical trials have showcased quick recuperation of respiratory failures among critical patients of COVID-19. According to independent researchers, RLF-100 apparently blocks the multiplication of the SARS coronavirus in human lung cells as well as monocytes.

The first rapid clinical recuperation report was posted by doctors from Houston Methodist Hospital. It described the recovery of a 54-year-old man who contracted COVID-19 while being treated for rejection of a multiple lung transplant and was taken off the ventilator within four days of treatment.

Similar outcomes were observed in more than 15 cases treated under emergency use IND (Investigational New Drug), sources claimed. The FDA extended its access protocols which are available to critically ill patients admitted to the current Phase 2/3 FDA trials

Sources with relevant information cited that critically ill COVID-19 patients witnessed a quick recovery from pneumonitis, as displayed by the findings on their x-ray reports. Moreover, an improvement in the patients’ blood oxygen levels were seen alongside a 50% decrease in test center markers related to COVID-19 inflammation.

Prof. Jonathan Javitt, CEO and Chairman of NeuroRx was reported stating that other antiviral agents have failed to show such fast recuperation from a viral disease and exhibited inhibitions towards the multiplication of the virus. He further said that placebo-controlled trials are being carried out by NeuroRx in order to analyze the observations made during open-label and case-control studies.

For those uninitiated, RF-100 is an antiviral agent that has been developed as a Material Threat Medical Countermeasure.

The FDA has reportedly granted Fast Track designation to this antiviral, which is developed through a joint venture agreement among National Institute of Health and numerous other federal agencies, the medicine is being developed as a Material Threat Medical Countermeasure.

 

Source Credits: https://www.prnewswire.com/news-releases/rlf-100-aviptadil-clinical-trial--showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells-301104384.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Razorpay: New funding en route, meteoric rise in market value expected
Razorpay: New funding en route, meteoric rise in market value expected
By Nikita Chaurasia

Indian startup Razorpay is reportedly in discussions with Singapore-based sovereign wealth fund GIC Pvt. Ltd. and other existing investors to raise around USD 200 million in a funding round that would allow the fintech company to double its valuation...

FDA to allow pharma companies modify COVID-19 shots amid variants surge
FDA to allow pharma companies modify COVID-19 shots amid variants surge
By Nikita Chaurasia

With the rising cases of Coronavirus variants, the United States Food & Drug Administration (FDA) has reportedly introduced guidelines for pharmaceutical companies to modify their COVID-19 vaccine doses in an effort to curb the spread of the dise...

Gan & Lee partners with IDF to expand its diabetes treatment portfolio
Gan & Lee partners with IDF to expand its diabetes treatment portfolio
By Nikita Chaurasia

China-based leading pharmaceutical organization Gan & Lee Pharmaceuticals Co. Ltd. has announced to have signed a strategic collaboration with the International Diabetes Federation (IDF) to bolster its efforts towards promoting the prevention and...

Google Pay under CCI investigation over antitrust claims in India
Google Pay under CCI investigation over antitrust claims in India
By Nikita Chaurasia

The Competition Commission of India (CCI) has reportedly begun an investigation to inspect if the renowned online payment system Google Pay has misused its dominance in the digital marketplace in the country. Sources close to the matter stated that ...

SpaceX’s valuation skyrockets with USD 850 million funding round
SpaceX’s valuation skyrockets with USD 850 million funding round
By Nikita Chaurasia

According to reliable sources, California-based aerospace manufacturer and space transportation services company SpaceX, headed by Tesla’s Chief Executive Elon Musk, recently completed an equity funding round of USD 850 million, post which the ...